The aim of the present work was to evaluate the effectiveness of oral treatment with eliglustat (EG), an inhibitor of glucosylceramide synthase, the first step of glycosphingolipid biosynthesis, in preventing the effects of Shiga toxin 2 (Stx2) in lethal and sublethal models of HUS in rats.<h4>Methods</h4>Male juvenile Sprague-Dawley rats (∼100 g body weight (bw)) were intraperitoneally injected with lethal (5 ng/g bw) or sublethal (1 ng/g bw) doses of Stx2, or eluent. Here, UGCG is linked to hemolytic-uremic syndrome.